UK Pays 25% More for US Meds Amidst PhRMA's Global Influence Push
The UK’s new agreement to pay 25% more for American pharmaceutical products isn't just a 'problematic precedent,' it's the predictable outcome of unchecked corporate power. While the Guardian frames this as a 'dynamic shift,' it's more of a rubber stamp on a strategy PhRMA has been executing for decades: leveraging trade deals and economic pressure to force other nations to abandon their more
fiscally responsible drug pricing models. For instance, the US-Mexico-Canada Agreement (USMCA) included provisions that extended patent protections for biologics, effectively driving up drug costs in Mexico and Canada to benefit US pharma. So, when US officials 'hope other countries will follow,' they're not merely expressing a wish; they're signaling intent backed by the full weight of a
government beholden to corporate lobbyists. (Indeed, PhRMA spent over $30 million on lobbying in 2023 alone, according to OpenSecrets.org, consistently ranking among the top lobbying industries.) How charitable of Uncle Sam to ensure global access to his pharmaceutical innovations, provided others agree to subsidize American healthcare costs by paying top dollar. Who needs a functioning healthcare
system when you can just export your exorbitant pricing model?